| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.86B | $ 2.36B | $ 1.89B | $ 1.49B | $ 1.13B |
| Gross Profit | $ 2.81B | $ 2.32B | $ 1.85B | $ 1.47B | $ 1.12B |
| Operating Income | $ 619.10M | $ 570.50M | $ 250.90M | $ 249.00M | $ 102.50M |
| EBITDA | $ 666.60M | $ 639.70M | $ 416.10M | $ 236.60M | $ 138.10M |
| Net Income | $ 478.60M | $ 341.30M | $ 249.70M | $ 154.50M | $ 89.60M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.48B | $ 1.08B | $ 1.03B | $ 989.30M | $ 711.30M |
| Total Assets | $ 4.63B | $ 3.72B | $ 3.25B | $ 2.37B | $ 2.07B |
| Total Debt | $ 415.30M | $ 455.10M | $ 428.40M | $ 262.90M | $ 440.40M |
| Net Debt | $ -297.70M | $ 222.10M | $ 177.30M | $ 0.00 | $ 99.60M |
| Total Liabilities | $ 1.38B | $ 1.13B | $ 1.02B | $ 660.90M | $ 698.50M |
| Stockholders' Equity | $ 3.25B | $ 2.59B | $ 2.23B | $ 1.71B | $ 1.37B |
| Cash Flow | |||||
| Free Cash Flow | $ 748.70M | $ 557.20M | $ 361.60M | $ 322.90M | $ 233.10M |
| Operating Cash Flow | $ 782.70M | $ 595.40M | $ 389.90M | $ 339.40M | $ 256.50M |
| Investing Cash Flow | $ -264.40M | $ -126.80M | $ -467.10M | $ -177.10M | $ -130.20M |
| Financing Cash Flow | $ -38.30M | $ -486.70M | $ 65.30M | $ -234.30M | $ 27.40M |
Neurocrine (CH:NB3)
:NB3
